RBC Capital raises price target on Neurocrine Biosciences

What happened: On June 29, RBC Capital raised its price target on Cameco Corporation (NYSE:CCJ) to C$175 from C$160, maintaining an "Outperform" rating. The firm cited Cameco's position among the top AI-powered grid stocks. Separately, on May 29, 2026, RBC increased its price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $183 from $180, also maintaining an "Outperform" rating. A bullish thesis on NBIX was published on TradersPro's Substack, highlighting the stock's valuation and potential.

Market impact: The upgrades reflect analysts' optimism in Cameco's exposure to the growing AI sector and Neurocrine's pipeline and valuation. This could drive investment in uranium mining (Cameco) and biotechnology (Neurocrine), potentially benefiting related companies and sectors.

What to watch next: Investors should monitor Cameco's Q2 earnings, due August 3, for updates on AI demand and uranium pricing. For Neurocrine, watch for the interim data from its phase 2 study of NBI-74788 in Parkinson's disease, expected in Q3 2023, and the company's Q2 earnings on July 27.